GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Apollon Formularies PLC (AQSE:APOL) » Definitions » Cyclically Adjusted PB Ratio

Apollon Formularies (AQSE:APOL) Cyclically Adjusted PB Ratio : 0.00 (As of Jun. 06, 2024)


View and export this data going back to . Start your Free Trial

What is Apollon Formularies Cyclically Adjusted PB Ratio?

As of today (2024-06-06), Apollon Formularies's current share price is £8.0E-5. Apollon Formularies's Cyclically Adjusted Book per Share for the fiscal year that ended in Dec21 was £0.03. Apollon Formularies's Cyclically Adjusted PB Ratio for today is 0.00.

The historical rank and industry rank for Apollon Formularies's Cyclically Adjusted PB Ratio or its related term are showing as below:

During the past 11 years, Apollon Formularies's highest Cyclically Adjusted PB Ratio was 0.05. The lowest was 0.00. And the median was 0.00.

AQSE:APOL's Cyclically Adjusted PB Ratio is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.885
* Ranked among companies with meaningful Cyclically Adjusted PB Ratio only.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Apollon Formularies's adjusted book value per share data of for the fiscal year that ended in Dec21 was £0.004. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is £0.03 for the trailing ten years ended in Dec21.

Shiller PE for Stocks: The True Measure of Stock Valuation


Apollon Formularies Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Apollon Formularies's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Apollon Formularies Cyclically Adjusted PB Ratio Chart

Apollon Formularies Annual Data
Trend Jun10 Jun11 Dec12 Dec13 Dec14 Dec17 Dec18 Dec19 Dec20 Dec21
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 2.80 0.89

Apollon Formularies Semi-Annual Data
Jun11 Jun12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec17 Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Jun23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.80 - 0.89 - -

Competitive Comparison of Apollon Formularies's Cyclically Adjusted PB Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Apollon Formularies's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Apollon Formularies's Cyclically Adjusted PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Apollon Formularies's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Apollon Formularies's Cyclically Adjusted PB Ratio falls into.



Apollon Formularies Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Apollon Formularies's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=8.0E-5/0.03
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Apollon Formularies's Cyclically Adjusted Book per Share for the fiscal year that ended in Dec21 is calculated as:

For example, Apollon Formularies's adjusted Book Value per Share data for the fiscal year that ended in Dec21 was:

Adj_Book=Book Value per Share/CPI of Dec21 (Change)*Current CPI (Dec21)
=0.004/117.6295*117.6295
=0.004

Current CPI (Dec21) = 117.6295.

Apollon Formularies Annual Data

Book Value per Share CPI Adj_Book
201006 0.001 91.962 0.001
201106 0.017 95.235 0.021
201212 0.000 96.871 0.000
201312 0.001 98.326 0.001
201412 0.001 99.070 0.001
201712 0.001 104.011 0.001
201812 0.120 105.998 0.133
201912 0.024 108.420 0.026
202012 0.073 109.897 0.078
202112 0.004 117.630 0.004

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Apollon Formularies  (AQSE:APOL) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Apollon Formularies Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Apollon Formularies's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Apollon Formularies (AQSE:APOL) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
6 Hope Street, Quayside House, Castletown, IMN, IM9 1AS
Apollon Formularies PLC is a London, England and Jamaican based medical cannabis pharmaceutical company specialising in research and treatment of patients with cancer and chronic pain. It is engaged in investing by seeking to acquire a direct and/or indirect interest in projects and assets in the agriculture and logistics sectors and the medicinal cannabis sector. The company focus on opportunities in Africa and Europe. It has created proprietary hybrid medical cannabis pharmaceutical strains, technology, formulations, and treatment products.

Apollon Formularies (AQSE:APOL) Headlines

From GuruFocus

Valuing Donald Yacktman's Portfolio: The Peter Lynch Fair Value

By Holly LaFon Holly LaFon 07-02-2012

First Pacific Advisors Buys Alcoa, Bank of America

By Tiziano Frateschi Tiziano Frateschi 10-16-2015

FPA Capital Fund 4th Quarter 2015 Commentary

By Holly LaFon Holly LaFon 02-08-2016

The Yacktman Focused Fund's Top Growth Stocks

By Dianne Tordillo Dianne Tordillo 01-25-2013

5 Stocks to Avoid - January 2017

By Benjamin Clark Benjamin Clark 01-14-2017

5-Star Predictable Companies with Highest ROA

By Holly LaFon Holly LaFon 03-20-2012

Apollo Education Group Is a Value Trap

By OPM Insights Nelson Hsu 10-15-2015

FPA Capital Fund Comments on Apollo Education Group Inc

By Vera Yuan Vera Yuan 02-19-2015

FPA Capital Fund Q1 2013 Commentary

By Holly LaFon Holly LaFon 04-24-2013

Sobering Findings About Student Debt

By OPM Insights Nelson Hsu 11-07-2015